• 1
    Rosen PP, Groshen S, Saigo PE, et al. A long-term follow-up study of survival in Stage I (T1NOMO) and Stage II (T1N1MO) breast carcinoma. J Clin Oncol 1989; 7: 35566.
  • 2
    Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status and survival in 14,740 breast cancer cases. Cancer 1989; 63: 1817.
  • 3
    Fisher B, Costantino J, Wickerham L, Redmond N, Wolmark R, Margolese D, et al. Adjuvant therapy for node-negative breast cancer: an update of NSABP findings. Proc Am Soc Clin Oncol 1993; 12: 69.
  • 4
    NIH Consensus Conference. Treatment of early-stage breast cancer. JAMA 1991; 265: 3918.
  • 5
    Fisher B, Slack NH, Bross IDJ, et al. Cancer of the breast: size of neoplasm and prognosis. Cancer 1969; 24: 107180.
  • 6
    Valagussa P, Bonadonna G, Veronesi U. Patterns of relapse and survival following radical mastectomy: analysis of 716 consecutive patients. Cancer 1978; 41: 11708.
  • 7
    Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status and survival in 24,740 breast cancer cases. Cancer 1989; 63: 1817.
  • 8
    Quiet C, Ferguson D, Weichselbaum R, Hellman S. The natural history of node negative breast cancer: predictors of outcome with 40 year follow-up. Proc Am Soc Clin Oncol 1993; 12: 73.
  • 9
    Fisher B, Redmond C, Fisher E, et al. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node-negative breast and Bowel Project Protocol B-06. J Clin Oncol 1988; 6: 107687.
  • 10
    LeDoussal V, Tubiana-Hulin M, Hacene K, et al. Nuclear characteristics as indicators of prognosis in node-negative breast cancer patients. Breast Cancer Res 1989; 14: 20716.
  • 11
    Aaltomaa S, Lipponen P, Eskelinen M, Kosma V, Marin S, Sinikka M, et al. Comparison of classic and quantitative prognostic factors in hormone receptor-positive and hormone receptor-negative female breast cancer. Am J Surg 1993; 165: 30711.
  • 12
    Gilchrist K, Gray R, Fowble B, Tormey D, Taylor S IV. Tumor necrosis is a histoprognosticator for early recurrence and death in Stage II breast cancer [abstract]. Lab Inves 1988; 58: 34A.
  • 13
    Kuhajda FP, Eggleston JC. Pregnancy associated plasma protein a and extensive necrosis: clinically significant predictors of early recurrence in Stage I estrogen receptor-negative breast carcinoma. Lab Invest 1985; 53: 1017.
  • 14
    Lee A, DeLellis R, Silverman M, Heatley G, Wolfe H. Prognostic significance of peritumoral lymphatic and blood vessel invasion in node-negative carcinoma of the breast. J Clin Oncol 1990; 8: 145765.
  • 15
    Pritchard KI, Trudeau ME, Chapman JW, Hanna W, Kahn H, Murray CA, et al. Prognostic variables in node-negative breast cancer: an all subset analysis. Proc Am Soc Clin Oncol 1993; 12: 73.
  • 16
    McCready DR, Hanna W, Kahn H, Mobbs BG, Fish EB, Lickley HLA, et al. Risk factors for local recurrence following lumpectomy for breast cancer without radiotherapy. Proc Am Soc Clin Oncol 1993; 12: 96.
  • 17
    Alanko A, Heinonen E, Scheinin T, Tolppanen E-M, Vihko R. Significance of estrogen and progesterone receptors, disease-free interval, and site of metastasis on survival of breast cancer patients. Cancer 1985; 56: 1696700.
  • 18
    Chevalier B, Heintzman F, Mosseri V, et al. Prognostic value of estrogen and progesterone receptors in operable breast cancer: results of a univariate and multivariate analysis. Cancer 1988; 62: 251724.
  • 19
    Mason B, Holdaway IM, Mullins P, Yee LH, Key RG. Progesterone and estrogen receptor status as prognostic variables in breast cancer. Cancer Res 1983; 43: 2985990.
  • 20
    Fisher B, Redmond C, Fisher ER, et al. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node-negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol 1988; 6: 107687.
  • 21
    McGuire WL, Clark GM, Dressier LG, et al. Role of steroid hormones receptors as prognostic factors in primary breast cancer. J Natl Cancer Inst Monogr 1986; 1: 1923.
  • 22
    Benner SE, Clark GM, McGuire WL. Review: steroid receptors, cellular kinetics, and lymph node status as prognostic factors in breast cancer. Am J Med Sci 1988; 296: 5966.
  • 23
    Thorpe SM, Rose C, Rasmussen BB, Mouridens HT, Bayer T, et al. Prognostic value of steroid hormone receptors: multivariate analysis of systemically untreated patients with node negative primary breast cancer. Cancer Res 1987; 47: 612633.
  • 24
    Winstanley J, Cooke T, George WD, Murray G, Holt S, Croton R, et al. The long term prognostic significance of oestrogen receptor analysis in early carcinoma of the breast. Br J Cancer 1991; 64: 99101.
  • 25
    King WJ, Gree GL. Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells. Nature (London) 1984; 307: 7457.
  • 26
    Pertshuk LP, Feldman JG, Eisenberg KB, Carter AC, Thelmo EL, et al. Immunocytochemical detection of progesterone receptor in breast cancer with monoclonal antibody: relation to biochemical assay, disease-free survival and clinical endocrine response. Cancer 1988; 62: 3429.
  • 27
    Allred DC, Bustamante MA, Daniel CO, Gaskill HC, Cruz AB. Immunocytochemical analysis of estrogen receptors in human breast carcinomas: evaluation of 130 cases and review of the literature regarding concordance with biochemical assay and clinical relevance. Arch Surg 1990; 125: 10713.
  • 28
    Battifora H, Mehta P, Ahn C, Esteban JM. Estrogen receptor immunocytochemical assay in paraffin embedded tissue: a better gold standard? Applied Immunohistochemistry 1993; 1: 3945.
  • 29
    McGuire WL, Chamness GC, Fugue SAW. The importance of normal and abnormal oestrogen receptor in breast cancer. Cancer Surv 1992; 14: 401.
  • 30
    McGuire WL, Chamness GC, Fugua SAW. Abnormal estrogen receptor in clinical breast cancer. J Steroid Biochem Molec Biol 1992; 43: 2437.
  • 31
    Kinsel LB, Szabo E, Greene GL, Konrath J, Leight GS, McCarty KS. Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: comparison with quantitative biochemical methods. Cancer Res 1989; 49: 10526.
  • 32
    Andersen J, Thorpe SM, King WJ, Rose C, Christensen I, et al. The prognostic value of immunohistochemical estrogen receptor analysis in paraffin-embedded and frozen section vs. that of steroid binding assays. Eur J Cancer 1990; 26: 4429.
  • 33
    Pertschuk LP, Kim DS, Nayer K, Feldman JG, Eisenberg EB, et al. Immunocytochemical estrogen and progestin receptor assay in breast cancer with monoclonal antibodies: histopathologic, demographic, and biochemical correlations and relationship to endocrine response and survival. Cancer 1990; 66: 166370.
  • 34
    Dressier LG, Bartow SA. DNA flow cytometry in solid tumors: practical aspects and clinical applications. Semin Diagn Pathol 1989; 6: 5582.
  • 35
    Hedley DW, Clark GM, Cornelisse CJ, Killander D, Kute T, et al. Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast. Cytometry 1993; 14: 4825.
  • 36
    Hedley DW, Rugg CA, Gelber RD. Association of DNA index and S-phase fraction with prognosis of nodes positive early breast cancer. Cancer Res 1987; 47: 472935.
  • 37
    Dressier LG. Are DNA flow cytometry measurements providing useful information in the management of the node negative breast cancer patient? Cancer Invest 1993; 10: 47786.
  • 38
    Brifford M, Spyratos F, Tubiana-Hulin M, et al. Sequential cytopunctures during pre-operative chemotherapy for breast cancer: cytomorphologic changes, initial tumor ploidy and tumor regression. Cancer 1989; 63: 6317.
  • 39
    Spyrotas F, Brifford M, Tubiana-Hulin M, et al. Sequential cyto-punctures during pre-operative chemotherapy for primary breast carcinoma: II. DNA flow cytometry changes during chemotherapy, tumor regression and short-term follow-up. Cancer 1992; 69: 4705.
  • 40
    Remvikos Y, Beuzobon P, Zadjela A, et al. Correlation of pre-treatment proliferative activity with response to cytotoxic chemotherapy. J Natl Cancer Inst 1989; 81: 13837.
  • 41
    Seymour L, Bezwoda WR, Meyer K. Response to second line hormone treatment for advanced breast cancer: predictive value of ploidy determination. Cancer 1990; 65: 27204.
  • 42
    Osborne CK. DNA flow cytometry in early breast cancer: a step in the right direction. J Natl Cancer Inst 1989; 81: 13445.
  • 43
    Dressier LG, Mangalik A, Bartow SA, et al. The use of DNA flow cytometry to characterize breast cancer cells affected by pre-surgical (neoadjuvant) chemotherapy. Proceed AACR 1992; 33: 213.
  • 44
    Dressier LG, Duncan M, Varsa E, McConnell T. DNA content measurement can be obtained using archival material for DNA flow cytometry: a comparison with cytogenetic analysis in 56 pediatric solid tumor. Cancer. 1993; 72: 203341.
  • 45
    Smeets AG, Pauwels RE, Beck TN, Geraedts TN, et al. Tissue specific markers in flow cytometry of urological cancers: comparing chromosomal and flow cytometric DNA analysis of bladder tumors. Int J Cancer 1987; 39: 30410.
  • 46
    Remvikos Y, Muleris M, Viehl PH, Salmon RJ, Dutrilaux B. DNA content and genetic-evaluation of human colorectal adenocarcinoma: a study by flow cytometry and cytogenetic analysis. Int J Cancer 1988; 42: 53943.
  • 47
    Siegfried TM, Ellison OT, Resan TH. Correlation of model chromosome number of cultured non-small cell lung carcinoma with DNA index of solid tumor tissue. Cancer Res 1991; 51: 325773.
  • 48
    Cornelisse CJ, van de Velde CJ, Caspers RJ, Moolenaar AJ, Hermans J. DNA ploidy and survival in breast patients. Cytometry 1987; 8: 22534.
  • 49
    Ferno M, Baldetorp B, Ewers SB, Olsson H, Sigurdsson H, Killander D. Flow cytometric DNA index and S-phase fraction in breast cancer in relation to other prognostic variables and to clinical outcome. Acta Oncol 1992; 31: 15765.
  • 50
    Kallioniemi OP, Blanco G, Alavaikko M, Hietanen T, Manila J, et al. Improving the prognostic value of DNA flow cytometry in breast cancer by combining DNA index and S-phase fraction: a proposed classification of DNA histograms in breast cancer. Cancer 1988; 62: 218390.
  • 51
    Beerman H, Kluin M, Hermans J, van de Velde CJH, Cornelisse CJ. Prognostic significance of DNA ploidy in a series of 690 primary breast cancer patients. Int J Cancer 1990; 45: 349.
  • 52
    Coulson PB, Thornthwaite JT, Wooley TW, Sugerbaker EV, Seckinger D. Prognostic indicators including DNA histogram type, receptor content and staging related to human breast cancer patient survival. Cancer Res 1984; 44: 418796.
  • 53
    Moran RE, Black HM, Alpert L, Straws HJ. Correlation of cell cycle kinetics, hormone receptor, histopathology and nodal status in human breast cancer. Cancer 1984; 54: 158690.
  • 54
    O'Reiller SM, Complejohn RS, Barnes DM, et al. Node negative breast cancer: prognostic subgroups defined by tumor size and DNA flow cytometry. J Clin Oncol 1990; 8: 20406.
  • 55
    Winchester DJ, Duda RB, August CZ, et al. The importance of DNA flow cytometry in node negative breast cancer. Arch Surg 1990; 125: 8869.
  • 56
    Clark GM, Dressier LG, Owens MA, et al. DNA flow cytometry predicts for relapse and survival in node negative breast cancer patients. N Engl J Med 1989; 320: 62733.
  • 57
    Dressier LG, Eudey L, Gray R, et al. Preliminary analysis the impact of DNA flow cytometry measurements to predict time to recurrence in the intergroups (INT 011) node negative clinical trial: an Eastern Cooperative Oncology Group Study. J Natl Cancer Inst Monogr 1992; 11: 16772.
  • 58
    Muss HB, Kute TE, Case LD, et al. The relationship of flow cytometry to clinical and biologic characteristics in women with node negative breast cancer. Cancer 1989; 64: 1894990.
  • 59
    Sigurdsson J, Baldetorp B, Borg A, et al. Indicators of prognosis in node negative breast cancer. N Engl J Med 1990; 322: 104553.
  • 60
    Fisher B, Gunduz N, Costantino J, et al. DNA flow cytometric analysis of primary operable breast cancer: relation of ploidy and S-phase fraction to prognosis of patients in NSABP B-04. Cancer 1991; 68: 146575.
  • 61
    Lewis WE. Prognostic significance of flow cytometric DNA analyses in node negative breast patients. Cancer 1990; 65: 231520.
  • 62
    Intergroup Trial (0102). SWOG 8897 ECOG 2188 CALGB 8897. Phase III comparison of adjuvant chemotherapy with or without endocrine therapy in high risk, node negative breast cancer patients and a natural history follow-up study in low risk, node negative patients. Activated August, 1989.
  • 63
    NSABP Protocol B-18. A ‘unified’ trial to compare short, intensive preoperative systemic adriamycin, cyclophosphamide therapy with similar therapy administered in conventional postoperative fashion: B18.2 a study to evaluate DNA histograms by flow cytometry.
  • 64
    Eastern Cooperative Oncology Group Laboratory study, EST 4189. Clinical significance and therapeutic impact of DNA flow cytometry measurements of ploidy and S-phase in Stage II breast cancer patients.
  • 65
    Southwest Oncology Group Laboratory Study, SWOG 8854, Intergroup 0104. Prognostic value of cytometry measurements of breast cancer DNA from postmenopausal patients with involved nodes and receptor positive tumors: a companion protocol to SWOG 8814.
  • 65
    Hupperets P, Volovics L, Schutte B, Schouten L, Jager J, Shouten H, et al. The prognostic value of flow cytometry (FCM) in Stage I and II breast cancer patients. Proc Am Soc Clin Oncol 1993; 12: 113.
  • 66
    Isola J, Visakorpi T, Holli K, Kallioniemi OP. Association of over-expression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 1992; 84: 1109.
  • 67
    Allred D, Clark G, Tandon A, et al. HER2/neu oncogene expression identified a group of node-negative breast cancer patients at high risk for recurrence. Presented at the American Society of Clinical Oncology Annual Meeting, Washington, DC, May 20–22, 1990.
  • 68
    May E, Mouriesse H, May-Levin F, Qian JF, May P, Delarue JC. Human breast cancer: identification of populations with a high risk of early relapse in relation to both oestrogen receptor status and c-erb-2 overexpression. Br J Cancer 1990; 62: 4305.
  • 69
    Patterson MC. Correlation between c-erb-2 amplification and risk of early relapse in node-negative breast cancer [abstract]. 17th Meeting of the International Society for Oncodevelopmental Biology and Medicine, Theoretical and Clinical Cancer Research, September 1989.
  • 70
    Borgen PI, Tiwari RK, Rossi J, Wong GY, Osborne MP. Amplification of Her2/neu oncogene is associated with early metastasis in human breast cancer [abstract]. Proc Annu Meeting Am Assoc Cancer Res 1990; 31: A1858.
  • 71
    Hartmann L, Ingle L, Wold G, Farr J, Krook J, Roche P. Prognostic value of Her2/neu overexpression in node-positive breast cancer: results from two randomized adjuvant Mayo/North Central Cancer Treatment Group trials. Proc Am Soc Clin Oncol 1993; 12: 84.
  • 72
    Gasparini G, Palma PD, Maluta S, Caffo P, Leonardi E, Meli S, et al. Expression of the c-erb-3 and c-erb-2 gene products lacks of prognostic value in node-negative breast carcinoma. Proc Am Soc Clin Oncol 1993; 12: 63.
  • 73
    Sainsbury R. Epidermal growth factor receptors and prognosis in breast cancer. Cancer Invest 1990; 8 (2): 2512.
  • 74
    Dickson RB. Simulatory and inhibitory growth factors and breast cancer. J Steroid Biochem Mol Biol 1990; 37: 795811.
  • 75
    Downward J, Yarden Y, Scrace G, Totty N, Rockwell P, Ullrich A, et al. Close similarity of epidermal growth factor receptor and c-erbB oncogene protein sequences. Nature 1984; 307: 5217.
  • 76
    Sainsbury JRC, Needham GK, Farndon JR, Malcolm AJ, Harris AL. Epidermal growth factor receptors and oestrogen receptors in human breast cancer. Lancet 1985; 1: 3646.
  • 77
    Sainsbury JRC, Needham GK, Farndon JR, Malcolm AJ, Harris AL. Epidermal growth factor receptor status as predictor of early recurrence and death from breast cancer Lancet 1987; 1: 1398402.
  • 78
    Nicholson S, Richard J, Sainsbury C, Halcrow P, Kelly P, Angus B, et al. Epidermal growth factor receptor (EGFr): results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup. Br J Cancer 1991; 63 (1): 14650.
  • 79
    Harris AL, Nicholson S, Sainsbury R, Wright C, Farndon J. Epidermal growth factor receptor and other oncogenes as prognostic markers. Natl Cancer Inst Monogr 1992; 11: 181187.
  • 80
    Spyratos F, Delarue JC, Andrieu C, Lidereau R, Champeme MH, Hacene K, et al. Epidermal growth factor receptors and prognosis in primary breast cancer. Breast Cancer Res Treat 1990; 17 (2): 839.
  • 81
    Foekens JA, van Putten WL, Portengen J, Rodenburg CJ, Reubi JC, Berns PM, et al. Prognostic value of p53 protein and receptors for epidermal growth factor (EGR-R), insulin-like growth factor-1 (IGF-1-R) and somatostatin (SS-R) in patients with breast and ovarian cancer. J Steroid Biochem Mol Biol 1990; 37 (6): 81521.
  • 82
    Bolla M, Chedin M, Souvignet C, Marron J, Arnou JdC, Chambaz E. Epidermal growth factors in intracranial and breast tumours: their clinical significance. Br J Cancer 1991; 63: 55360.
  • 83
    Grimaux M, Romain S, Remvikos Y, Martin PM, Magdelenat H. Prognostic value of epidermal growth factor receptor in nodepositive breast cancer. Breast Cancer Res Treat 1989; 14: 7790.
  • 84
    Costa S, Stamm J, Almendral A, Ludwig H, Wyss R, Fabbro D, et al. Predictive value of EGF receptor in breast cancer. Lancet 1988; 2: 12589.
  • 85
    Macias A, Perez R, Hagerstrom T, Skoog L. Transforming growth factor alpha in human mammary carcinomas and their metastases. Anticancer Res 1989; 9 (1): 1779.
  • 86
    Toi M, Osaki A, Yamada H, Toge T. Epidermal growth factor receptor expression as a prognostic indicator in breast cancer. Eur J Cancer 1991; 27: 97780.
  • 87
    Bolla M, Chedin M, Colonna M, Marron J, Rostaing-Puissant B, Chambaz E. Prognostic value of epidermal growth factor receptor in a series of 303 breast cancers. Eur J Cancer 1992; 28A: 10524.
  • 88
    Gasparini G, Gullick WJ, Bevilacqua P, Sainsbury JR, Meli S, Boracchi P, et al. Human breast cancer: prognostic significance of the c-erbB2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features. J Clin Oncol 1992; 10 (5): 68695.
  • 89
    Lewis S, Locker A, Todd JH, Bell JA, Nicholson R, Elston CW, et al. Expression of epidermal growth factor receptor in breast carcinoma. J Clin Pathol 1990; 43 (5): 3859.
  • 90
    Coombes RC, Barrett-Lee P, Luqmani Y. Growth factor expression in breast tissue. J Steroid Biochem Mol Biol 1990; 37: 83340.
  • 91
    Nicholson S, Sainsbury JR, Halcrow P, Chambers P, Farndon JR, Harris AL. Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrence breast cancer. Lancet 1989; 1: 1825.
  • 92
    Westley B, Rochefort H. A secreted glycoprotein induced by estrogen in human breast cancer cell lines. Cell 1980; 20: 35262.
  • 93
    Morisset M, Capony F, Rochefort H. The 52 kDa estrogen-induced protein secreted by MCF7 cells is a lysosomal acidic protease. Biochem Biophys Res Commun 1986; 138: 1029.
  • 94
    Augereau P, Garcia M, Mattei MG, Cavailles V, Depadova F, Derocq D, et al. Cloning sequencing of the 52K cathepsin-D complementary DNA of MCF7 breast cancer cells and mapping on chromosome II. Mol Endocrinol 1988; 2: 18692.
  • 95
    Capony F, Rougeot C, Montcourrier P, Vacailles V, Salazar G, Rochefort H. Increased secretion, altered processing, and glycosylation of pro-cathepsin-D in human mammary cells. Cancer Res 1989; 49: 39049.
  • 96
    Capony F, Morisset M, Barrett AJ, Capony JP, Briozzo P, Vignon F, et al. Phosphorylation, glycosylation, and proteolytic activity of the 52K estrogen induced protein of MCF-7 cells. J Cell Biol 1987; 104: 25362.
  • 97
    Rochefort H, Cavailles V, Augereau P, Capony F, Maudelonde T, Touitou I, et al. Overexpression and hormonal regulation of pro-cathepsin D in mammary and endometrial cancer. J Steroid Biochem 1989; 34: 17782.
  • 98
    Touitou I, Cavailles V, Garcia M, Defrenne A, Rochefort H. Differential regulation of Cathepsin D by sex steroids in mammary cancer and uterine cells. Mol Cell Endocrinol 1989; 66: 2318.
  • 99
    Cavailles V, Augereau P, Garcia M, Rochefort H. Estrogens and growth factors induce MRNA of the pro cathepsin D secreted by breast cancer cell. Nucl Acid Res 1988; 16: 190319.
  • 100
    Vignon F, Capony F, Chambon M, Freiss G, Garcia M, Rochefort H. Autocrine growth stimulation of the MCF 7 breast cancer cells by the estrogen-regulated 52 K protein. Endocrinology 1986; 118: 153745.
  • 101
    Mathieu M, Rochefort, Brenton B, Prebois C, Vignon F. Interactions of cathepsin-D and insulin-like growth factor-II (IGF-II) on the IGF-II/mannose-6-phosphate receptor in human breast cancer cells and possible consequences on mitogenic activity of IGF-II. Mol Endocrinol 1990; 4: 132735.
  • 102
    Rochefort H, Capony F, Garcia M. Cathepsin-D: a protease involved in breast cancer metastasis. Cancer Metastasis Rev 1990; 9: 32131.
  • 103
    Briozzo P, Badet J, Capony F, Pieri I, Montcourrier P, Barritault D, et al. MCF-7 mammary cancer cells respond to bFGF and internalize it following its release for extracellular matrix: a permissive role of Cathepsin-D. Exp Cell Res 1991; 194: 2529.
  • 104
    Garcia M, Derocq D, Pujol P, Rochefort H. Overexpression of transfected Cathepsin-D in transformed cells increases their malignant phenotype and metastatic potency. Oncogene 1990; 5: 180913.
  • 105
    Briozzo P, Morisset M, Capony F, Rougeot C, Rochefort H. Invirro degradation of extracellular matrix with Mw 52,000 cathepsin-D secreted by cancer cells. Cancer Res 1988; 48: 368892.
  • 106
    Rogler H, Freiss G, Besse M-G, Cavalle-Carthez G, Garcia M, Pau B, et al. Two-site immunoenzymatic assay for the 52 kDa Cathepsin-D in cytosols of breast cancer tissues. Clin Chem 1989; 35: 815.
  • 107
    Thorp SM, Rochefort H, Garcia M, Freiss G, Christensen IJ, Khalaf S, et al. Association between high concentration of Mw 52,000 Cathepsin-D and poor prognosis in primary human breast cancer. Cancer Res 1989; 49: 600814.
  • 108
    Spyratos F, Brouillet JP, Defrenne A, Hacene K, Rouesse J, Maudelonde T, et al. Cathepsin-D: an independent prognostic factor for metastasis of breast cancer. Lancet 1989; 2: 11158.
  • 109
    Romaine S, Muraceiole X, Varette I, Bressac C, Brandone H, Martin PM. La Cathepsin-D: unfacteur pronostique independant dans le cancer du sein. Bull Cancer (Paris) 1990; 75 (5): 43947.
  • 110
    Duffy MJ, Broulliet JP, Reilly D, McDermott E, O'Higgins N, Fennelly JJ, et al. Cathepsin-D concentration in breast cancer cytosols: correlation with biochemical, histological and clinical findings. Clin Chem 1991; 37: 1014.
  • 111
    Namer M, Ramalole A, Fontana X, Etienne MC, Hery M, Jourlait A, et al. Prognostic value of total Cathepsin-D in breast cancer. Breast Cancer Res Treat 1991; 19: 8993.
  • 112
    Granata G, Coradini D, Cappelletti V, DiFronzo G. Prognostic relevance of Cathepsin-D vs. oestrogen receptors in node-negative breast cancer. Eur J Cancer 1991; 27: 9702.
  • 113
    Janicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Hofler H, et al. Urikonase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Canc Res Treat 1993; 24 (3): 195208.
  • 114
    Spyratos F, Martin PM, Hacene K, Romain S, Andrieu C, Ferrero-Pous M, et al. Multiparametric prognostic evaluation of biological factors in primary breast cancer. J Natl Cancer Inst 1992; 84 (16): 126672.
  • 115
    Kute TE, Shao L-M, Sugg K, Long RT, Russell GB, Case LD. Cathepsin-D as a prognostic indicator for node-negative breast cancer patients using both immunoassays and enzymatic assays. Cancer Res 1992; 52: 16.
  • 116
    Pujol P, Maudelonde T, Daures JP, Rouanet JP, Brouillet JP, Pujol H, et al. Prospective study on the prognostic values of Cathepsin-D levels in breast cancer. Cancer. 1993; 71: 200612.
  • 117
    Winstanley JH, Leinster SJ, Cooke TG, Westley BR, Platt-Higgins AM, Rudland PS. Prognostic significance of Cathepsin-D in patients with breast cancer. Br J Cancer 1993; 67 (4): 76772.
  • 118
    Isola J, Weitz S, Visakorpi T, Holli K, Shea R, Khabbaz N, et al. Cathepsin-D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer. J Clin Oncol 1993; 11 (1): 3643.
  • 119
    Kandalaft PL, Chang KL, Ahn CW, Traweek ST, Mehta P, Battifor H. Prognostic significance of immunohistochemical analysis of Cathepsin-D in low stage breast cancer. Cancer 1993; 71 (9): 275663.
  • 120
    Henry JA, McCarthy AL, Angus B, Westley BR, May FE, Nicholson S, et al. Prognostic significance of the estrogen-regulated protein, Cathepsin-D, in breast cancer: an immunohistochemical study. Cancer 1990; 65: 26571.
  • 121
    Tandon AK, Clark GM, Chamness GC, Chirgwin JM, McGuire WL. Cathepsin-D and prognosis in breast cancer. N Engl J Med 1990; 322: 297302.
  • 122
    Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 46.
  • 123
    Bicknell R, Harris AL. Novel growth regulatory factors and tumour angiogenesis. Eur J Cancer 1991; 27: 7815.
  • 124
    Alguire GH, Chalkley HW, Legallais FY, et al. Vascular reactions of normal and malignant tumors in-vivo: I. vascular reactions of mice to wounds and to normal and neoplastic transplants. J Natl Cancer Inst 1945; 6: 7385.
  • 125
    Folkman J, Cole P, Zimmerman S. Tumor behavior in isolated perfused organis: in-vitro growth and metastasis of biopsy material in rabbit thyroid and intestinal segment. Ann Surg 1966; 164: 491502.
  • 126
    Srivasta A, Laidler P, Davies RP, Horgan K, Hughes LE. The prognostic significance of tumor vascularity in intermediate thickness (0.76–4.0 mm thick) skin melanoma: a quantitative histologic study. Am J Pathol 1988; 133: 41923.
  • 127
    Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 18.
  • 128
    Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989; 339: 5861.
  • 129
    Chodak GW, Haudenschild C, Gittes RF, Folkman J. Angiogenic activity as a marker of neoplastic and preneoplastic lesions of the human bladder. Ann Surg 1980; 192: 76271.
  • 130
    Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastases and angiogenesis: an imbalance of positive and negative regulation. Cell 1991; 64: 32736.
  • 131
    Dickson RB. Regulation of tumor-host interactions in breast cancer. J Steroid Biochem Mol Biol 1992; 41: 389400.
  • 132
    Horak ER, Leek R, Klenk N, Lejeune S, Smith K, et al. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 1992; 340: 11204.
  • 133
    Gasparini G, Folkman J, Possa F, Bevilacque P, Meli S, Weidner N. Tumor angiogenesis (TA) quantitation by factor VIII-related antigen immunocytochemistry: a new, highly significant, and independent prognostic indicator (PI) in early stage breast carcinoma (ESBC) [abstract]. Proc Am Soc Clin Oncol 1992; 11: A40.
  • 134
    Khanuja PS, Fregene T, Gimotty P, George J, Pienta KJ. Angiogenesis does not predict recurrence in patients with primary breast cancer. Proc Am Soc Clin Oncol 1993; 12: 67.
  • 135
    Battiwalla ZF, Shethna YI. An antiserum to tumour angiogenesis factor: therapeutic approach to solid tumours. Anticancer Res 1989; 9: 180914.
  • 136
    Levine AJ, Moman J, Finlay CA. The p53 tumour suppressor gene. Nature 1991; 351: 4536.
  • 137
    Chen LC, Neubauer A, Kurisu W, Waldman FM, Ljung BM, et al. Loss of heterozygosity on the short arm of chromosome 17 is associated with high proliferative capacity and DNA aneuploidy in primary human breast cancer. Proc Natl Acad Sci 1991; 88: 384751.
  • 138
    Varley JH, Brammer WJ, Lane DP, Swallow TE, Dolan C, et al. Loss of chromosome 17[13 sequences and mutation of p53 in human breast carcinomas. Oncogene 1991; 6: 41321.
  • 139
    Vogelstein B, Kinsler KW. p53 function and dysfunction cell. 1992; 70: 5236.
  • 140
    Zambetti GP, Quartin RS, Martinez J, Georgoff I, Momand J, et al. Regulation of transformation and the cell cycle by p53. Cold Spring Harbor Symposia on Quantitative Biology 1991; 56: 291225.
  • 141
    Davidoff AM, Herndon JE, Glover NS, Kerns BJ, Pence JC, et al. Relation between p53 overexpression and established prognostic factors in breast cancer. Surgery 1991; 110: 25964.
  • 142
    Isola J, Visakorpi T, Holli K, Kallioniemi OP. Association of over-expression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 1992; 84: 110914.
  • 143
    Lin D, Shields MT, Ullrich SJ, Appella E, Mercer WE. Growth arrest induced by wild-type p53 protein blocks cells prior to or near the restriction point in late G1 phase. Proc Natl Acad Sci 1992; 89: 92104.
  • 144
    Lane DP. p53 Guardian of the genome. Nature 1992; 358: 156.
  • 145
    Michalovitz D, Halvey O, Oren M. p53 Mutations: gains or losses? J Cell Biochem 1991; 45: 229.
  • 146
    Iwaya K, Tsuda H, Jiraide H, Tamaki K, Syouetsu T, et al. Nuclear p53 immunoreaction associated with poor prognosis of breast cancer. Jpn J Cancer Res 1991; 82: 83540.
  • 147
    Thor AD, Moor DH, Edgerton SM, Kawasaki ES, Reihsaus E, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancer. J Natl Cancer Inst 1992; 84: 84555.
  • 148
    Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993; 85: 2006.
  • 149
    Bosari S, Lee AKC, Heatley GJ, Coggi G. Abnormal p53 immunoreactivity and prognosis in node-negative breast carcinomas with long-term follow-up. Virchows Arch [A] 1992; 421: 2915.
  • 150
    Barnes DM, Dublin EA, Fisher CJ, Levison DA, Millis RR. Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis. Hum Pathol 1993; 24: 46976.
  • 151
    Crawford LV, Pirn DC, Bulbrook RD. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 1982; 30: 4038.
  • 152
    Schlichtholz B, Legros Y, Gillet D, Gaillard C, Marty M, et al. The immuno response to p53 in breast cancer patients is directed against the immunodominant epitopes unrelated to the mutational hotspot. Cancer Res 1992; 52: 63804.
  • 153
    Poller DN, Roberts EC, Bell JA, Elstron CW, Blarney RW, Ellis IO. The p53 protein expression in mammary ductal carcinoma in situ: relationship to immunohistochemical expression of estrogen receptor and c-erbB-2. Hum Pathol 1993; 24: 4638.
  • 154
    Bartkova J, Bartek J, Vojtesek B, Lukas J, Rejthar A, et al. Immunochemical analysis of the p53 oncoprotein in matched primary and metastatic human tumours. Eur J Cancer 1993; 29A: 8816.
  • 155
    Grondahl-Hansen J, Thorpe SM, Rosenquist C, Christensen IJ, Rasmussen BB, Pyke C, et al. High levels of u-PA and PAI-1 in cytosols from breast cancer tissue are associated with poor prognosis. 3rd International Workshop on the Molecular and Cellular Biology of Plasminogen Activation, Elsinore, 1991, May 8–13.
  • 156
    Janicke F, Schmitt M, Graeff H. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemost 1991; 17: 30312.
  • 157
    Mori K, Fujii R, Kida N, Takahashi H, Ohkubo S, Fujino M, et al. Complete primary structure of the human estrogen-responsive gene (pS2) product. J Biochem 1990; 107 (1): 736.
  • 158
    Thim L. A new family of growth factor-like peptides ‘Trefoil’ disulphide loop structures as a common feature in breast cancer associated peptide (pS2), pancreatic spasmolytic polypeptide (PSP), and frog skin peptides (spasmolysin). FEBS Lett 1989; 250 (1): 8590.
  • 159
    Nunez AM, Berry M, Imler JL, Chambon P. The 5′ flanking region of the pS2 gene contains a complex enhancer region responsive to oestrogens, epidermal growth factor, a tumour promoter (TPA), the C-Ha-ras oncoprotein and the c-jun protein. EMBO J 1989; 8 (3): 8239.
  • 160
    Cappelletti V, Coradini D, Scanziani E, Benini E, Silvestrini R, DiFronzo G. Prognostic relevance of pS2 status in association with steroid receptor status and proliferative activity in node-negative breast cancer. Eur J Cancer 1992; 28A (8–9): 13158.
  • 161
    Schwartz LH, Koerner FC, Edgerton SM, Sawicka JM, Rio MC, Bellocq JP, et al. pS2 expression and response to hormonal therapy in patients with advanced breast cancer. Cancer Res 1991; 51 (2): 6248.
  • 162
    Klijn JG, Berns PM, Bontenbal M, Alexieva-Figusch J, Foekens JA. Clinical breast cancer, new developments in selection and endocrine treatment of patients. J Steroid Biochem Mol Biol 1992; 43 (1–3): 21121.
  • 163
    Ciocca DR, Fuque SA, Lock-Lim S, Toft DO, Welch WJ, McGuire WL. Response of human breast cancer cells to heat shock and chemotherapeutic drugs. Cancer Res 1992; 52 (13): 364854.
  • 164
    Thor A, Benz C, Moore D II, Goldman E, Edgerton S, Landry J, et al. Stress response protein (srp-27) determination in primary human breast carcinomas: clinical, histologic, and prognostic correlations. J Natl Cancer Inst 1991; 83 (3): 1708.
  • 165
    Ciocca DR, Clark GM, Tandon AK, Fuque SA, Welch WJ, McGuire WL. Heat shock protein hsp70 in patients with axillary lymph node negative breast cancer: prognostic implications. J Natl Cancer Inst 1993; 85 (7): 5704.
  • 166
    Robertson JF, Dixon AR, Nicholson RI, Ellis IO, Elstron CW, Blarney RW. Confirmation of a prognostic index for patients with metastatic breast cancer treated by endocrine therapy. Breast Cancer Res Treat 1992; 22 (3): 2217.
  • 167
    Galea MH, Blarney RW, Elstron CE, Ellis IO. The Nottingham prognostic index in primary breast cancer. Breast Cancer Res Treat 1992; 22 (3): 20721.
  • 168
    Albain KS, Green S, LeBlanc M, Rivkin S, O'Sullivan J, Osborne CK. Proportional hazards and recursive partitioning and amalgamation analyses of the Southwest Oncology Group node-positive adjuvant CMFVP breast cancer data base: a pilot study. Breast Cancer Res Treat 1992; 22 (3): 263273.
  • 169
    Ravdin PM, Clark GM. A practical application of neural network analysis for predicting outcome of individual breast cancer patients. Breast Cancer Res Treat 1992; 22 (3): 28593.
  • 170
    Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992; 339: 115, 71–85.
  • 171
    Neville AM, Bettleheim R, Gelber RD. Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. J Clin Oncol 1992; 10: 696705.
  • 172
    Hillner BE, Smith TJ. A model of chemotherapy in node-negative breast cancer. Natl Cancer Inst Monogr 1992; 11: 1439.
  • 173
    Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972; 34: 187200.
  • 174
    Tibshirani R. A plain man's guide to the proportional hazards model. Clin Invest Med 1982; 5: 638.
  • 175
    Erlichman C, Warde P, Gadalla T, Ciampi A, Baskerville T. RECPAM analysis of prognostic factors in patients with Stage III breast cancer. Breast Cancer Res Treat 1990; 16 (3) 23142.
  • 176
    Breiman L, Freidman JH, Olshen RA. Classification and regression trees. Belmont, CA: Wadsworth, 1984.
  • 177
    McGuire WL. Breast cancer prognostic factors: evaluation guidelines. J Natl Cancer Inst 1991; 83: 1545.
  • 178
    Van Houwelingen JC, LeCessie S. Predictive value of statistical models. Stat Med 1990; 9: 130325.